Skip to main content
EWTX
NASDAQ Life Sciences

Officer Files Intent to Sell $5.17M in Edgewise Therapeutics Stock, Continuing Recent Sales Trend

Analysis by Wiseek.aiReviewed by Editorial Team
Sentiment info
Negative
Importance info
8
Price
$28.73
Mkt Cap
$3.042B
52W Low
$10.6
52W High
$30.48
Market data snapshot near publication time

summarizeSummary

An officer at Edgewise Therapeutics has filed a Form 144 indicating intent to sell approximately $5.17 million worth of common stock, following over $9.4 million in sales over the past three months.


check_boxKey Events

  • Officer Files Intent to Sell

    An officer, Robert Michael Carruthers, has filed a Form 144 to sell 183,867 shares of common stock, valued at approximately $5.17 million, acquired through option exercise.

  • Sustained Insider Selling

    This proposed sale follows previous dispositions by the same officer, totaling 367,537 shares with gross proceeds of over $9.41 million within the last three months, indicating a continuous reduction in holdings.

  • Significant Executive Exposure Reduction

    The cumulative value of recent and proposed sales by this executive represents a substantial decrease in their direct ownership, which may be interpreted as a lack of conviction or a move to diversify.


auto_awesomeAnalysis

An officer at Edgewise Therapeutics has filed a Form 144 indicating intent to sell approximately $5.17 million worth of common stock. While the shares were acquired through the exercise of options under a registered plan, this proposed sale adds to a pattern of significant dispositions by the same officer, who has already sold over $9.4 million in stock within the past three months. This sustained reduction in insider holdings, even if partially driven by option exercises, represents a notable decrease in executive exposure to the company's stock and could be viewed as a negative signal by investors.

At the time of this filing, EWTX was trading at $28.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $10.60 to $30.48. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed EWTX - Latest Insights

EWTX
Feb 26, 2026, 8:05 AM EST
Filing Type: 10-K
Importance Score:
8
EWTX
Feb 26, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
EWTX
Jan 20, 2026, 4:14 PM EST
Filing Type: 144
Importance Score:
8
EWTX
Jan 15, 2026, 4:45 PM EST
Filing Type: 144
Importance Score:
7